FDA
-
-
-
-
-
-
-
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
-
-
-
-
-
-
-
Panbela (PBLA) announces publication of clinical data from studies of CPP-1X in neuroblastoma
-
-
-
-
-
-
-
Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification
-
-
-
-
-
-
-
Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101
-
-
-
-
-
-
-
Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi
-
-
-
-
-
-
-
Panbela Therapeutics to Receive a Total Up to $9.5 Million for Divestiture of Assets within Eflornithine (DFMO) Pediatric Neuroblastoma Program to US WorldMeds
-
-
-
-
-
-
-
Panbela Therapeutics (PBLA) Enters Research Agreement for Polyamine Metabolic Inhibitor Therapy in Combination with CAR-T Cell Therapy
-
322,245 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

